DIA会员及用户请点击登录

登录

忘记用户 ID? or 忘记密码?

Not a Member?

创建账户并加入。

McCormick Place

2017 年 06 月 18 日 8:30 上午 - 2017 年 06 月 18 日 12:00 下午

2301 South Martin Luther King Jr. Drive, Gate 4, Chicago, IL 60616

#25: Regulatory Considerations for Drug Development: Current Status and Trend of IND/NDA Practice in China

Instructors

Daniel  Liu, PhD, MSc

Daniel Liu, PhD, MSc

President & CSO, Beijing Clinical Service Center, China

Daniel Liu, PhD, has served for more than two decades in global clinical research departments, in both management and operations, for such multinational drug companies as Novartis, Pfizer, Sanofi, Schering-Plough, Johnson & Johnson, and Medidata. Dr. Liu has served as Core Expert of the NMPA CDE clinical data standardization Committee, and as Vice Chairman of the China Clinical Trial Data Management Group, an advisory member of DIA China committee, and a part-time professor of the NMPA Institute of Exceutive Development, a part-time professor of China Pharmaceutical University. He has taught more than 60 clinical research courses at home and abroad. He earned his PhD from the University of Illinois School of Pharmacy.

Earl W. Hulihan, MEd

Earl W. Hulihan, MEd

Professor, SUTCM, United States

Professor Hulihan is Principal with ew hulihan and associates, inc. For over 35+ years, Hulihan has been active in the DIA, in Medicine, as well as providing regulatory consulting, auditing, and training services to the global pharmaceutical community and regulatory authority personnel worldwide.

获得信息并保持参与

不要错失任何机会——请加入我们的邮件列表,了解DIA的观点和事件。